多学科的团队对抗血栓治疗管理和临床结果在老年人与心房动:一个目标试验仿真
Maïwenn Prunel1, Alexis Cochard1,2, Leila Abbas1
1Institut Pierre Louis d'Épidémiologie Et de Santé Publique (IPLESP), Sorbonne Université, INSERM, Paris, 75013, France.
BMC medicine
|September 30, 2025
概括
在老年人心肌 (AF) 中管理抗血栓剂的多学科团队会议并没有减少不良结果. 这种方法在六个月内预防死亡,血栓栓塞或严重出血方面没有显著的益处.
科学领域:
- 老年医学 老年医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 国际指导方针建议多学科,以患者为中心的管理心房动 (AF),包括抗血栓治疗.
- 多学科AF小组对复杂,高风险的子组,如非常老和脆弱的临床有效性仍在研究中.
- 目前缺乏关于专门的抗血栓管理团队对老年AF患者临床结果的影响的证据.
研究的目的:
- 评估医院多学科团队 (MDT) 会议的影响,重点是抗血栓管理.
- 评估MDT会议对死亡,主要血栓塞栓事件或重大/临床相关出血的复合结果的影响.
- 在6个月的随访期内确定MDT抗血栓治疗在老年人 (≥75岁) 患有AF的临床益处.
主要方法:
- 未来的多中心队列研究涉及818名75岁以上的AF或心房的患者.
- 针对性试验模拟方法 (克隆,审查,权重) 应用于来自五个急性老年病科的观察数据.
- 主要暴露:参加医院MDT会议 (老年医生,心脏病专家,神经血管专家,静血专家) 在45天内;6个月的随访.
主要成果:
- 该研究包括818名患者;138人 (16.9%) 属于MDT会议组 (平均年龄89岁,57%为女性).
- 主要复合结局的6个月累计发病率相似:35.3% (MDT组) 与36.2% (对照组).
- 在MDT和对照组之间没有观察到主要复合结果的显著差异 (风险差异-0.9%;95%CI, -7.5至6.0;p=0.79).
结论:
- 在老年AF患者中进行抗血栓治疗的医院多学科团队会议并没有减少死亡,主要血栓塞栓症或主要出血的复合结果.
- 研究结果表明,在研究期间,这种特定的MDT方法在高风险人群中没有显著的临床益处.
- 由于观测设计和残留混杂的可能性,应谨慎解释结果.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
328
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
328
Therapeutic Drug Monitoring: Affecting Factors
201
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
201
Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220


